These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15228400)

  • 1. Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes.
    Philpott A; Chandy S; Morris R; Horowitz JD
    Intern Med J; 2004 Jun; 34(6):361-3. PubMed ID: 15228400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
    Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
    Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
    Stewart S; Voss DW; Northey DL; Horowitz JD
    Ther Drug Monit; 1996 Dec; 18(6):635-9. PubMed ID: 8946658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris.
    Liberts EA; Willoughby SR; Kennedy JA; Horowitz JD
    Eur J Pharmacol; 2007 Mar; 560(1):49-55. PubMed ID: 17292880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
    Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
    Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics.
    Horowitz JD; Sia ST; Macdonald PS; Goble AJ; Louis WJ
    Int J Cardiol; 1986 Nov; 13(2):219-29. PubMed ID: 3793279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perhexiline--stable plasma concentrations with formulation change.
    Siebert WJ; Gabb GM; Wing LM
    Aust N Z J Med; 1996 Oct; 26(5):707-8. PubMed ID: 8958370
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
    J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
    Sallustio BC; Westley IS; Morris RG
    Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perhexiline maleate in coronary insufficiency. Clinical research].
    Fleury G; Massabie R
    Nouv Presse Med; 1974 Nov; 3(37):2411-2. PubMed ID: 4459841
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
    Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
    Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation.
    Kennedy JA; Beck-Oldach K; McFadden-Lewis K; Murphy GA; Wong YW; Zhang Y; Horowitz JD
    Eur J Pharmacol; 2006 Feb; 531(1-3):13-9. PubMed ID: 16413015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.
    Parker JD; Bart BA; Webb DJ; Koren MJ; Siegel RL; Wang H; Malhotra B; Jen F; Glue P
    Crit Care Med; 2007 Aug; 35(8):1863-8. PubMed ID: 17522570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
    Montalescot G; Sideris G; Meuleman C; Bal-dit-Sollier C; Lellouche N; Steg PG; Slama M; Milleron O; Collet JP; Henry P; Beygui F; Drouet L;
    J Am Coll Cardiol; 2006 Sep; 48(5):931-8. PubMed ID: 16949482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats.
    Licari G; Somogyi AA; Milne RW; Sallustio BC
    Xenobiotica; 2015 Jan; 45(1):3-9. PubMed ID: 25050791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.